LitCovid-sample-sentences  

PMC:7205724 / 20480-23259 JSONTXT 25 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T164 0-51 Sentence denotes 6 Development of a human monoclonal antibody (mAb)
T165 53-81 Sentence denotes 6.1 Targeting the S protein
T166 83-101 Sentence denotes 6.1.1 Hypothesis:
T167 102-179 Sentence denotes A mAb against the binding domain of the virus can inhibit SARS-CoV2 infection
T168 180-466 Sentence denotes Recently, hybridoma supernatants containing antibody repertoires from immunized transgenic mice that express the human immunoglobulin heavy and light chains and rat origin immunoglobulin constant regions were used to detect antibodies that can cross neutralize SARS-S and SARS-2-S [26].
T169 467-687 Sentence denotes One chimeric 47D11 H2L2 antibody displayed such a cross-neutralizing activity, decreased syncytia formation induced by SARS-S and SARS2-S, and could protect VeroE6 cells against SARS-S and SARS2-S pseudotyped virus [26].
T170 688-820 Sentence denotes It may lie in its similar affinities for interacting with the same domain of the S1 subunit, i.e., S1B, of each SARS-S and SARS-2-S.
T171 822-838 Sentence denotes 6.1.2 Rational:
T172 839-923 Sentence denotes The chimeric 47D11 H2L2 might not be effective in human lung cells as it is in vitro
T173 924-1024 Sentence denotes 47D11 carried a higher affinity for interacting with the S2 subunit of SARS-S than that of SARS-2-S.
T174 1025-1206 Sentence denotes It is important that for both SARS-S and SARS-2-S, the binding of the 47D11 antibody to the target – the S1B domain – does not block the binding of S1B and S2 to ACE2 receptor [26].
T175 1207-1326 Sentence denotes By contrast, neutralizing antibodies that specifically target SARS-S could compete with S1B and S2 for binding to ACE2.
T176 1328-1369 Sentence denotes 6.2 Targeting pro-inflammatory cytokines
T177 1371-1389 Sentence denotes 6.2.1 Hypothesis:
T178 1390-1440 Sentence denotes A mAb against IL6 can attenuate hyper inflammation
T179 1441-1769 Sentence denotes Tocilizumab, also known as atlizumab, is a humanized anti-human IL6 receptor antibody approved by FDA for several inflammatory and autoimmune diseases severe, such as cytokine release syndrome, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systematic juvenile idiopathic arthritis.
T180 1770-1851 Sentence denotes It is safe and effective for both adults and children two years of age and older.
T181 1853-1870 Sentence denotes 6.2.2 Rationale:
T182 1871-1950 Sentence denotes Tocilizumab can treat lung injury in patients with critical and severe COVID-19
T183 1951-2098 Sentence denotes In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy.
T184 2099-2317 Sentence denotes Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels.
T185 2318-2376 Sentence denotes Also, lung lesion opacity was absorbed in 90% of patients.
T186 2377-2456 Sentence denotes Neither serious adverse effects nor deaths occurred with tocilizumab treatment.
T187 2457-2563 Sentence denotes There are ongoing clinical trials for tocilizumab treatment in patients with moderate and severe COVID-19.
T188 2564-2779 Sentence denotes Currently, the use of Tocilizumab is recommended for patients with COVID-19 who have warning signs of hyper inflammation, as can be measured by IL6, ferritin, platelet counts, inflammatory markers, and H score [28].